Magnetic resonance imaging perfusion is associated with disease severity and activity in multiple sclerosis

PurposeThe utility of perfusion-weighted imaging in multiple sclerosis (MS) is not well investigated. The purpose of this study was to compare baseline normalized perfusion measures in subgroups of newly diagnosed MS patients. We wanted to test the hypothesis that this method can differentiate between groups defined according to disease severity and disease activity at 1 year follow-up.MethodsBaseline magnetic resonance imaging (MRI) including a dynamic susceptibility contrast perfusion sequence was performed on a 1.5-T scanner in 66 patients newly diagnosed with relapsing-remitting MS. From the baseline MRI, cerebral blood flow (CBF), cerebral blood volume (CBV), and mean transit time (MTT) maps were generated. Normalized (n) perfusion values were calculated by dividing each perfusion parameter obtained in white matter lesions by the same parameter obtained in normal-appearing white matter. Neurological examination was performed at baseline and at follow-up approximately 1 year later to establish the multiple sclerosis severity score (MSSS) and evidence of disease activity (EDA).ResultsBaseline normalized mean transit time (nMTT) was lower in patients with MSSS >3.79 (p = 0.016), in patients with EDA (p = 0.041), and in patients with both MSSS >3.79 and EDA (p = 0.032) at 1-year follow-up. Baseline normalized cerebral blood flow and normalized cerebral blood volume did not differ between these groups.ConclusionLower baseline nMTT was associated with higher disease severity and with presence of disease activity 1 year later in newly diagnosed MS patients. Further longitudinal studies are needed to confirm whether baseline-normalized perfusion measures can differentiate between disease severity and disease activity subgroups over time.

[1]  Johannes Buchmann,et al.  10 Expanded Disability Status Scale (EDSS) , 2007 .

[2]  F. Barkhof,et al.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process , 2015, Nature Reviews Neurology.

[3]  Pamela W Schaefer,et al.  MR perfusion imaging in acute ischemic stroke. , 2011, Neuroimaging clinics of North America.

[4]  Leif Østergaard,et al.  Principles of cerebral perfusion imaging by bolus tracking , 2005, Journal of magnetic resonance imaging : JMRI.

[5]  A. Karantanas,et al.  Regional MRI Perfusion Measures Predict Motor/Executive Function in Patients with Clinically Isolated Syndrome , 2014, Behavioural neurology.

[6]  F. Barkhof,et al.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients , 2015, Nature Reviews Neurology.

[7]  J. De Keyser,et al.  Predictive value of clinical characteristics for ‘benign’ multiple sclerosis , 2007, European journal of neurology.

[8]  S. Vukusic,et al.  Natural history of multiple sclerosis: a unifying concept. , 2006, Brain : a journal of neurology.

[9]  Hans Lassmann,et al.  Cortical demyelination and diffuse white matter injury in multiple sclerosis. , 2005, Brain : a journal of neurology.

[10]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[11]  A. Karantanas,et al.  Hemodynamic evidence linking cognitive deficits in clinically isolated syndrome to regional brain inflammation , 2014, European journal of neurology.

[12]  7 T MRI : New Vision of Microvascular Abnormalities in Multiple Sclerosis , 2008 .

[13]  Christopher Coello,et al.  Correction of partial volume effect in 18F-FDG PET brain studies using coregistered MR volumes: Voxel based analysis of tracer uptake in the white matter , 2013, NeuroImage.

[14]  O. Ciccarelli,et al.  MRI CRITERIA FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS: MAGNIMS CONSENSUS GUIDELINES , 2016, The Lancet Neurology.

[15]  H. Wiendl,et al.  Clinical Relevance of Brain Volume Measures in Multiple Sclerosis , 2014, CNS Drugs.

[16]  N. Maurits,et al.  Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review , 2001, Multiple sclerosis.

[17]  H. Lassmann.  Axonal injury in multiple sclerosis , 2003, Journal of neurology, neurosurgery, and psychiatry.

[18]  M. Freedman,et al.  Aggressive multiple sclerosis: proposed definition and treatment algorithm , 2015, Nature Reviews Neurology.

[19]  A. Feinstein,et al.  Robust Perfusion Deficits in Cognitively Impaired Patients with Secondary-Progressive Multiple Sclerosis , 2013, American Journal of Neuroradiology.

[20]  C. Lucchinetti,et al.  Pathology of Multiple Sclerosis: Where Do We Stand? , 2013, Continuum.

[21]  G. Salemi,et al.  Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity , 2005, Neurology.

[22]  Maria Liguori,et al.  Age‐related disability in multiple sclerosis , 2002, Annals of neurology.

[23]  M. Reiser,et al.  Dynamic Contrast-Enhanced Magnetic Resonance Imaging Suggests Normal Perfusion in Normal-Appearing White Matter in Multiple Sclerosis , 2016, Investigative radiology.

[24]  W. Rashid,et al.  Multiple sclerosis. , 2012, BMJ clinical evidence.

[25]  H. Weiner,et al.  Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. , 2015, JAMA neurology.

[26]  P. Vermersch,et al.  Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis , 2011, The Lancet Neurology.

[27]  Yulin Ge,et al.  Seven-Tesla magnetic resonance imaging: new vision of microvascular abnormalities in multiple sclerosis. , 2008, Archives of neurology.

[28]  Wanyong Shin,et al.  Quantitative cerebral perfusion using dynamic susceptibility contrast MRI: Evaluation of reproducibility and age‐ and gender‐dependence with fully automatic image postprocessing algorithm , 2007, Magnetic resonance in medicine.

[29]  G J Barker,et al.  Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations , 2001, Neurology.

[30]  K. Walhovd,et al.  A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity , 2015, PloS one.

[31]  R M Weisskoff,et al.  Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. , 2006, AJNR. American journal of neuroradiology.

[32]  A. Bjørnerud,et al.  Cortical thickness and surface area relate to specific symptoms in early relapsing–remitting multiple sclerosis , 2015, Multiple sclerosis.

[33]  B. Cree,et al.  Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? , 2014, JAMA neurology.

[34]  Hans Lassmann,et al.  Hypoxia-like tissue injury as a component of multiple sclerosis lesions , 2002, Journal of the Neurological Sciences.

[35]  O. Ciccarelli,et al.  Brain atrophy and lesion load predict long term disability in multiple sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[36]  R. Poston,et al.  Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis , 1989, Journal of the Neurological Sciences.

[37]  G. Tedeschi,et al.  Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study , 2014, Multiple sclerosis.

[38]  A. Bjørnerud,et al.  An Automatic Procedure for Normalization of Cerebral Blood Volume Maps in Dynamic Susceptibility Contrast−Based Glioma Imaging , 2009, American Journal of Neuroradiology.

[39]  G V McDonnell,et al.  Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors , 1999, Journal of neurology, neurosurgery, and psychiatry.

[40]  Glyn Johnson,et al.  Dynamic susceptibility contrast perfusion MR imaging of multiple sclerosis lesions: characterizing hemodynamic impairment and inflammatory activity. , 2005, AJNR. American journal of neuroradiology.

[41]  Andrew Simmons,et al.  Reproducible segmentation of white matter hyperintensities using a new statistical definition , 2016, Magnetic Resonance Materials in Physics, Biology and Medicine.

[42]  G. Johnson,et al.  Perfusion Magnetic Resonance Imaging Correlates of Neuropsychological Impairment in Multiple Sclerosis , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[43]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[44]  A. Bjørnerud,et al.  Reduced perfusion in white matter lesions in multiple sclerosis. , 2015, European journal of radiology.

[45]  Michael Hutchinson,et al.  New perspectives in the natural history of multiple sclerosis , 2010, Neurology.

[46]  C. Wegner,et al.  Inflammation, demyelination, and degeneration - recent insights from MS pathology. , 2011, Biochimica et biophysica acta.

[47]  M. Horsfield,et al.  Gray matter damage predicts the accumulation of disability 13 years later in MS , 2013, Neurology.

[48]  Douglas C. Miller,et al.  Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.